drugset / Trial / NCT06334874

Study of the Efficacy and Safety of Antioxidants Astaxanthin as an Adjuvant Therapy for Community Acquired Pneumonia Patients.

NCT06334874

Phase 4 Unknown 80 enrolled Future University in Egypt
RandomizedParallel-groupTriple-blindTreatment

Summary

Community acquired pneumonia (CAP) is one of the most common and morbid conditions encountered in clinical practice, which causes serious morbidity worldwide. In CAP, oxidative stress is linked to inflammation, demonstrated by increased production of interleukin (IL)-6 and tumor necrosis factor (TNF)-α, which attract inflammatory cells and increase oxidant production by these cells. Attenuation of oxidative stress via antioxidants would be expected to result in reduced pulmonary damage. Antioxidants have been found to be effective in alleviating lung injury and protecting against damage of other organs.

Timeline

Start
2024-04-01
Primary completion
2024-07-01
Completion
2024-08-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Astaxanthin Small molecule 12 mg Oral

Indications